Benefits of heart failure-specific pharmacotherapy in frail hospitalised patients: a cross-sectional study.

ABSTRACT:

Objectives

Up to 50% of heart failure (HF) patients may be frail and have worse clinical outcomes than non-frail patients. The benefits of HF-specific pharmacotherapy (beta-blockers, ACE-inhibitors/angiotensin-receptor-blockers and mineralocorticoid-receptor-antagonist) in this population are unclear. This study explored whether HF-specific pharmacotherapy improves outcomes in frail hospitalised HF patients.

Design

Observational, multicentre, cross-sectional study.

Settings

Tertiary care hospitals.

Participants

One thousand four hundred and six hospitalised frail HF patients admitted between 1 January 2013 and 31 December 2020.

Measures

The Hospital Frailty Risk Score (HFRS) determined frailty status and patients with HFRS ≥5 were classified as frail. Th

SUBMITTER: Sharma Y 

PROVIDER: S-EPMC9486223 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature